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a b s t r a c t
Quinine, chloroquine and meﬂoquine are commonly used to treat malaria, however, with associated
gastrointestinal (GI) side-effects. These drugs act as antagonists at recombinant 5-HT3 receptors and
modulate gut peristalsis. These gastrointestinal side effects may be the result of antagonism at intestinal
5-HT3 receptors. Ileum from male C57BL/6 mice and guinea pigs was mounted longitudinally in organ
baths. The concentration–response curves for 5-HT and the selective 5-HT3 agonist 2-Me-5-HT were
obtained with 5-HT (pEC50¼7.5770.33, 12) more potent (P¼0.004) than 2-Me-5-HT (pEC50¼5.457
0.58, n¼5) in mouse ileum. There was no difference in potency of 5-HT (pEC50¼5.4270.15, n¼8)
and 2-Me-5-HT (pIC50¼5.0170.55, n¼11) in guinea pig ileum (P40.05). Quinine, chloroquine or
meﬂoquine was applied for 10 min and inhibitions prior to submaximal agonist application. In mouse
ileum, quinine, chloroquine and meﬂoquine antagonised 5-HT-induced contractions (pIC50¼4.970.17,
n¼7; 4.7670.14, n¼5; 6.2170.2, n¼4, correspondingly) with meﬂoquine most potent (Po0.05).
Quinine, chloroquine and meﬂoquine antagonised 2-me-5-HT-induced contractions (pIC50¼6.3570.11,
n¼8; 4.6470.2, n¼7; 5.1170.22, n¼6, correspondingly) with quinine most potent (Po0.05).
In guinea-pig ileum, quinine, chloroquine and meﬂoquine antagonised 5-HT-induced contractions
(pIC50¼5.0270.15, n¼6; 4.5470.1, n¼7; 5.3270.13, n¼5) and 2-me-5-HT-induced contractions
(pIC50¼4.6270.25, n¼5; 4.5670.14, n¼6; 5.6770.12, n¼4) with chloroquine least potent against
5-HT and meﬂoquine most potent against 2-me-5-HT (Po0.05). These results support previous studies
identifying anti-malarial drugs as antagonists at recombinant 5-HT3 receptors and may also demonstrate
the ability of these drugs to inﬂuence native 5-HT3 receptor-evoked contractile responses which may
account for their associated GI side-effects.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Enterochromafﬁn (EC) cells, within the epithelial layer of the
gastrointestinal tract, release 5-HT and account for 90% of the
body's store of 5-HT (Bueno, 2005). A variety of 5-HT receptors
located on intestinal cells modulate peristalsis (Tuladhar et al.,
2003, 1997, 2000) and secretions (Turvill et al., 2000). These
include 5-HT1A, 5-HT3 5-HT4, and 5-HT7 receptors (Hoyer et al.,
2002). 5-HT3 receptors play an important role in the excitability of
the enteric nervous system, contributing to fast excitatory post-
synaptic potentials in neurones of the myenteric and submucosal
plexuses (Galligan, 2002, 2000; Michel et al., 2005). 5-HT3 recep-
tors are distributed throughout the human, guinea pig, rat and
mouse intestine (Butler et al., 1990; Champaneria et al., 1992;
Chetty et al., 2006, 2008; Gaddum and Picarelli, 1957; Kapeller et
al., 2011), and play a pivotal role in modulating intestinal motility
(Chetty et al., 2006; Liu et al., 2011; Mayer et al., 2006). Addition-
ally, 5-HT3 receptor antagonists such as ramosetron have been
indicated for diarrhoea-predominant irritable bowel syndrome by
blocking intestinal 5-HT3 receptors (Lee et al., 2011).
The principal side effects of quinine, chloroquine and meﬂo-
quine include gastrointestinal disturbances such as nausea, vomit-
ing, diarrhoea and constipation (Barrett et al., 1996; Fogh et al.,
1988; White, 1992). This may be partially due to an interaction
with receptors or ion channels expressed within the gut and the
enteric nervous system. Quinine is known to block voltage-gated
Kþ channels (Schmalz et al., 1998) and chloroquine may indirectly
modulate large Ca2þ-activated Kþ channels (BKca) in the ileum
(Jing et al., 2013). Quinine, chloroquine, and meﬂoquine have also
been shown to act as antagonists at human and mouse recombi-
nant 5-HT3A homo-oligomeric receptors expressed in Xenopus
oocytes (Thompson et al., 2007; Thompson and Lummis, 2008).
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Additionally, quinine, chloroquine and meﬂoquine can displace
[3H]granisteron binding to mouse recombinant 5-HT3 receptors
(Thompson et al., 2007) indicating that these anti-malarial drugs
directly bind to the 5-HT binding site on the receptor. We
hypothesise that these anti-malarial drugs, quinine, chloroquine
and meﬂoquine will also act as antagonists at native 5-HT3
receptors in the small intestine, and by doing so may signiﬁcantly
attenuate 5-HT3-mediated contractions. In an attempt to investi-
gate this hypothesis, we have utilised both mouse and guinea-pig
isolated ileum preparations and examined the ability of the anti-
malarial compounds, quinine, chloroquine and meﬂoquine to
antagonise 5-HT and 5-HT3 mediated contractions. The rationale
for using both mouse and guinea pig ileum being that the action
of anti-malarial compounds at recombinant mouse 5-HT3A homo-
oligomeric receptors has been evaluated previously (Thompson
et al., 2007) and the guinea-pig 5-HT3A subunit (Lankiewicz et al.,
2000) has a 85% sequence homology with its human counterpart
with relatively similar agonist pharmacology to human recombi-
nant 5-HT3A receptors (Belelli et al., 1995).
2. Materials and methods
2.1. Preparation of tissues
Male C57BL/6 mice (25–35 g; Charles River Laboratories, Mar-
gate, UK) were killed by cervical dislocation and the ileum was
excised 2 cm before the ileo-caecal junction and placed in Tyrode's
solution (in mM: NaCl 137, KCl 2.7, CaCl2 1.8, MgCl2 1.0, NaH2PO4
0.42, NaHCO3 12.0, Glucose 5.5, pH 7.4). Segments of whole ileum
(3–4 cm) were then carefully mounted longitudinally in 50 ml
water jacketed organ baths containing Tyrode's solution continu-
ously aerated with 95% O2/5% CO2 and kept at 35–37 1C. The ileum
segments were allowed to equilibrate for 30 min whilst mechani-
cally attached to a force transducer with a resting tension of 0.5 g.
The contractile responses were recorded by the forced transducer
and visualised by means of a chart recorder.
Portions of guinea pig ileum were obtained from adult male
guinea pigs (200–300 g, Charles River, Laboratories, Margate, UK).
The ileumwas cut into 3.5–4 cm and mounted in a similar manner
to that of mouse ileum. The tissues were equilibrated for 30 min
followed by an initial application of acetylcholine (ACh; 1 mM) to
establish the integrity of the tissue at the start of the experiment.
All procedures involving animals were approved by the University
of Kent Animal Welfare and Ethical Review Body in accordance
with the UK Animals (Scientiﬁc Procedures) Act (1986).
2.2. Drugs
Acetylcholine, chloroquine, quinine (Sigma Aldrich, Poole, UK),
5-hydroxytryptamine hydrochloride (Tocris Bioscience, Bristol,
UK), 2-methyl-5-HT (Tocris Bioscience, Bristol, UK) were dissolved
in Tyrode's solution. Meﬂoquine (Sigma Aldrich, Poole, UK) was
dissolved in 50% dimethyl sulfoxide then diluted in Tyrode's
solution to a ﬁnal dimethyl sulfoxide concentration of r0.3%.
5-HT and 2-methyl-5-HT were applied to the serosal layer of the
ileum and responses recorded for 30 se which was sufﬁcient for
capturing the maximal contraction evoked from the drug. The
Tyrode's solution was then ﬂushed and the organ bath ﬁlled with
fresh Tyrode's solution. The ileum was then maintained for 10 min
prior to application of the next agonist concentration. For the anti-
malarial (antagonist) compounds, application was also made to
the serosal layer, however the ileum remained in contact with the
anti-malarial compounds for 10 min. Following this 10 min inter-
val, agonist was applied in the manner described above and the
agonist evoked response recorded. The application of antagonists
was not initiated until at least two agonist baseline responses
(mm) in the absence of an antagonist did not differ greater
than 5%.
2.3. Analysis of results
To construct the 5-HT and 2-me-5-HT agonist concentration–
response curves, individual agonist-evoked contractile response
heights (mm) were normalised to the maximal contraction height
for each ileum. The mean normalised responses 7S.E.M. for each
agonist concentration in a series were iteratively ﬁtted using
GraphPad Prism (version 6, Iowa, USA) to the non-linear regres-
sion equation
y¼ Eminþ
ðEmaxEminÞ
1þ10ðlogEC50 LÞnH
where Emin is the baseline contraction, Emax is the maximal
agonist-evoked contraction, EC50 is the concentration of the
agonist required to produce 50% of the maximal contraction, L
is the log of the agonist concentration and nH is the Hill slope.
Agonist potency was expressed as EC50 and pEC50 is the negative
log of the EC50.
For antagonist experiments, baseline agonist response heights
(mm) were measured and antagonist effects were measured as a %
of the mean baseline agonist response for each ileum preparation.
The relationships between increasing antimalarial (antagonist)
concentration and % inhibition of agonist concentration-evoked
contractions were iteratively ﬁtted using GraphPad Prism (version
6, Iowa, USA) to the non-linear regression equation
y¼ 100
1þ10ðlogIC50LÞnH
where IC50 is the concentration of the antagonist required to
reduce to 50% of the agonist contraction, L is the log of the
antagonist concentration and nH is the Hill slope. Agonist potency
was expressed as IC50 and pIC50 is the negative log of the IC50.
5-HT and 2-me-5-HT pEC50s were compared independently for
mouse and guinea pig by a Student's t-test, whilst pIC50s for each
antagonist against 5-HT and 2-me-5-HT were compared by a
oneway analysis of variance (ANOVA) followed by post-hoc ana-
lysis (Tukey's t). Statistical signiﬁcance was deﬁned as Po0.05.
3. Results
3.1. Mouse tissue
Both 5-HT and 2-methyl-5-HT were able to evoke concentration-
dependent contractions in mouse ileum tissue 5-HT which was
signiﬁcantly more potent in its ability to induce contraction of the
ileum than 2-methyl-5-HT (Fig. 1). Potency (expressed as pEC50) for
5-HT was 7.5770.33 (n¼12), whilst potency for 2-methyl-5-HT was
5.4570.58 (n¼5) (Table 1), which was signiﬁcantly greater than
potency for 5-HT when compared to the selective 5-HT3 agonist
(Student's t-test, t¼3.36, df¼15, P¼0.004). With increasing concen-
trations, quinine was able to successfully antagonise 5-HT-induced
(25 nM) contractions in mouse ileum (pIC50¼4.970.17, n¼7,
Fig. 2A) with complete block at 300 mM. Chloroquine also antag-
onised 5-HT induced contractions (pIC50¼4.7670.14, n¼5, Fig. 2B)
as did meﬂoquine (pIC50¼6.2170.2, n¼4, Fig. 2C) (Table 2). A one-
way analysis of variance revealed a statistically signiﬁcant difference
in the potency of the antimalarials to act as antagonists of the 5-HT
mediated contractions [F(2, 13)¼17.90, Po0.001] with meﬂoquine
acting as the most potent antagonist of 5-HT mediated contractions
(Tukey's t, Po0.05). A 10 min wash was sufﬁcient to reinstate
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5-HT-evoked contractions following the highest concentration of
either quinine or chloroquine, but not meﬂoquine.
Quinine (pIC50¼6.3570.11, n¼8), chloroquine (pIC50¼4.647
0.2, n¼7), and meﬂoquine (pIC50¼5.1170.22, n¼6) also success-
fully antagonised contractions evoked by the selective 5-HT3
antagonist, 2-methyl-5-HT (10 mM) in mouse ileum (Fig. 3). Meﬂo-
quine was also able to successfully antagonise 2-methyl-5-HT-
induced contractions with complete block at 100–300 mM. A
one-way analysis of variance revealed a statistically signiﬁcant
difference in the potency of the antimalarials to act as antagonists
of the 5-HT3 mediated contractions [F(2, 18)¼28.82, Po0.0001]
with quinine acting as the most potent antagonist of 5-HT3
mediated contractions (Tukey's t, Po0.05).
3.2. Guinea-pig tissue
5-HT (from 10 nM to 100 mM) and the selective 5-HT3
agonist 2-methyl-5-HT (from 10 nM to 30 mM) produced
concentration-dependent contractions in isolated guinea pig ileum.
Potency (expressed as pEC50) for 5-HT was 5.4270.15, whilst
potency for 2-methyl-5-HT was 5.0170.55 with no statistical
signiﬁcant difference in potency between the two agonists (Student's
t-test, t¼0.619, df¼17, P¼0.544, Fig. 4) (Table 1). Increasing con-
centrations of quinine and chloroquine were able to antagonise
submaximal 5-HT-induced contractions (pIC50¼5.0270.15, n¼6
and pIC50¼4.5470.1, n¼7, correspondingly) (Fig. 5A and B). Follow-
ing a 10 min wash, 5-HT-evoked contractions were reinstated. In a
similar manner, increasing concentrations of meﬂoquine also antag-
onised submaximal 5-HT contractions (pIC50¼5.3270.13, n¼5,
respectively, Fig. 5C) (Table 3), however, 5-HT-evoked contractions
could not be sufﬁciently restored in ileum treated with the maximal
concentration of meﬂoquine (300 μM) following three successive
washes (i.e., 45 min). A one-way analysis of variance revealed a
statistically signiﬁcant difference in antagonist potency across the
three anti-malarial compounds [F(2, 14)¼8.874, Po0.01] with chlor-
oquine least potent in inhibiting 5-HT-induced contractions in the
Fig. 1. (A) 5-HT (●) and 2-me-5-HT (○) induced contractions in mouse ileum. 5-HT (pEC50¼7.5770.33, n¼12) was more potent (Student's t-test, t¼3.36, df¼15, Po0.01)
than 2-Me-5-HT (pEC50¼5.4570.58, n¼5). (B) 5-HT and 2-me-5-HT induced contractions in the guinea-pig ileum. Concentration-dependent contractions produced by 5-HT
(pEC50¼5.4270.15, n¼8) and the selective 5-HT3 agonist 2-Me-5-HT (5.0170.55, n¼11) were not signiﬁcantly different (Student's t-test, t¼0.619, df¼17, P¼0.544) in
guinea pig ileum. Results are expressed as mean7S.E.M.
Fig. 2. Quinine (●), chloroquine (○) and meﬂoquine (□) block 5-HT-induced
contractions in isolated mouse ileum. Increasing concentrations of quinine
(pIC50¼4.970.17, n¼7), chloroquine (pIC50¼4.7670.14, n¼5) and meﬂoquine
(pIC50¼6.2170.2, n¼4) were able to antagonise 5-HT induced contractions in
mouse ileum, with meﬂoquine signiﬁcantly more potent (Tukey's t, Po0.05).
Results are expressed as mean7S.E.M.
Fig. 3. Quinine (●), chloroquine (○) and meﬂoquine (□) block 2-me-5-HT-induced
contractions in isolated mouse ileum. Increasing concentrations of quinine
(pIC50¼6.3570.11, n¼8), chloroquine (pIC50¼4.6470.2, n¼7) and meﬂoquine
(pIC50¼5.1170.22, n¼3) were able to antagonise 2-me-5-HT induced contractions
in mouse ileum, with quinine signiﬁcantly more potent (Tukey's t, Po0.05). Results
are expressed as mean7S.E.M.
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guinea pig ileum (Tukey's t, Po0.05). In addition, quinine
(pIC50¼4.6270.25, n¼5), chloroquine (pIC50¼4.4670.14, n¼6)
and meﬂoquine (pIC50¼5.6770.12, n¼4) were able to block selec-
tive 5-HT3 receptor mediated contractions by antagonising submax-
imal 2-methyl-5-HT-evoked responses (10 mM) in a concentration
dependent manner (Fig. 5). All but meﬂoquine were reversible
within 10 min of wash. A one-way analysis of variance revealed a
statistically signiﬁcant difference in antagonist potency [F(2, 12)¼
10.51, Po0.01) with meﬂoquine acting as the most potent antagonist
of 5-HT3 mediated contractions (Tukey's t, Po0.05).
4. Discussion
The main ﬁndings of the current investigation are that the
antimalarial compounds quinine, chloroquine and meﬂoquine
antagonise 5-HT-evoked contractions of both mouse and guinea-
pig ileum. These drugs also antagonise 5-HT3 receptor mediated
contractions. The ability of these drugs to signiﬁcantly inﬂuence
the activity of key intestinal modulators, such as 5-HT, may
underlie or partially account for their associated GI side effects
of these drugs.
5-HT and the selective 5-HT3 receptor agonist 2-me-5-HT
produced concentration-dependent contractions in mouse and
guinea-pig ileal tissue. The potency of 5-HT to produce contractions
in guinea pig ileum tissue (pEC50: 5.42) is very similar to previous
studies which reported potencies (pEC50) obtained in the presence
of methysergide (e.g., 5.32, 5.38) (Butler et al., 1990; Eglen et al.,
1990). The potency of the selective 5-HT3 agonist, 2-me-5-HT
(pEC50: 5.01), was also very similar to previous reports (e.g.,
5.44.91) (Butler et al., 1990, 1988; Eglen et al., 1990) adding
validity to our investigation. Interestingly, 5-HT was signiﬁcantly
more potent as an agonist than 2-me-5-HT in producing contractile
responses in mouse ileum, suggesting the possibility that a variety
of 5-HT receptor subtypes may be responsible for 5-HT-evoked
contraction in the mouse ileum. This is consistent with previous
studies which report a greater potency for 5-HT in the mouse ileum
compared to 5-HT application with 5-HT1,2,4,5,6,7 antagonism and 5-
HT potency compared to 2-me-5-HT (Chetty et al., 2006).
The antimalarial compounds also blocked contractions evoked
by 5-HT and 2-me-5-HT in mouse ileum. Interestingly, meﬂoquine
was signiﬁcantly more potent in antagonising 5-HT mediated
contractions then either chloroquine or meﬂoquine. This pattern
of antagonism is very similar to previous reports which found that
meﬂoquine was signiﬁcantly more potent in antagonising 5-HT-
induced current responses in mouse recombinant 5-HT3A homo-
oligomeric receptors (Thompson et al., 2007). However, when
looking at the antagonism of 2-me-5-HT mediated contractions,
we found that quinine was a signiﬁcantly more potent antagonist.
This difference may be due to expression native 5-HT3AB hetero-
oligomeric receptor in the mouse gut (Matsumoto et al., 2013)
which may be more sensitive to quinine antagonism than homo-
oligomeric 5-HT3A receptors, although no studies of recombinant
mouse 5-HT3AB hetero-oligomers have been completed to date.
What also must be considered is that the contractions would be
mediated by native receptors which may possess different reg-
ulatory sites compared to recombinant receptors, as well as being
modulated by different cellular machinery compared to expression
systems such as Xenopus oocytes.
The antimalarial compounds quinine, chloroquine and meﬂo-
quine were also able to antagonise both 5-HT and selective 5-HT3
receptor evoked contractions in guinea pig ileal tissue. Interest-
ingly, the antagonist action of the antimalarial compounds on
native receptors expressed in tissue is very similar to previous
reports of antagonist action of antimalarial compounds on recom-
binant receptors. Thompson et al. (2007, 2008) expressed human
and mouse recombinant 5-HT3 receptors in Xenopus oocytes and
measured 5-HT3 receptor-mediated inward current responses via
two-electrode voltage clamping. As with the current study, both
quinine and meﬂoquine antagonised agonist induced responses
with complete block at 100–300 μM, remarkably similar to the
present results from native receptors expressed in guinea-pig
tissue. The rank order of antagonist potency of 5-HT3 receptor
mediated contractions in guinea pig ileum, with meﬂoquine
signiﬁcantly more potent than quinine or chloroquine, was extre-
mely similar to the antimalarial antagonism of current responses
mediated by recombinant human 5-HT3AB hetero-oligomers
reported by Thompson and Lummis (2008). Based on previous
studies, it is likely that the native receptors expressed in the
guinea pig ileum are hetero-oligomeric receptors, and the biophy-
sical proﬁle of native 5-HT3 receptors is similar to that of human
5-HT3AB hetero-oligomers (Zhou and Galligan, 1999). This may
explain the similar antagonist proﬁle observed in this study.
Fig. 4. Quinine (●), chloroquine (○) and meﬂoquine (□) block 5-HT-induced
contractions in isolated guinea-pig ileum. Increasing concentrations of quinine
(pIC50¼5.0270.15, n¼6), chloroquine (pIC50¼4.5470.1, n¼7) and meﬂoquine
(pIC50¼5.3270.13, n¼6) were able to antagonise 5-HT induced contractions in the
guinea pig ileum with complete block at 100 mM and 300 mM applications for
quinine and meﬂoquine. Results are expressed as mean7S.E.M.
Fig. 5. Quinine (●), chloroquine (○) and meﬂoquine (□) block 2-me-5-HT-induced
contractions in isolated guinea-pig ileum. Increasing concentrations of quinine
(pIC50¼4.627 0.25, n¼5), chloroquine (pIC50¼4.5670.14, n¼6) and meﬂoquine
(pIC50¼5.6770.12, n¼4) were able to antagonise 2-me-5-HT induced contractions
in the guinea pig ileum. Results are expressed as mean7S.E.M.
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It was noted that for guinea-pig and mouse ileum experiments,
the antimalarial compounds were able to block contractions
induced by the non-selective agonist 5-HT. As there are other
5-HT receptors expressed within the intestine (e.g., 5-HT1A, 5-HT4
and 5-HT7) and these receptors may also induce or inﬂuence
contractile responses, it raises the question as to whether quinine
and meﬂoquine also have afﬁnity for other 5-HT receptors in
addition to 5-HT3. Receptor binding experiments and subsequent
docking studies conducted by Thompson et al. (2007) indicated
that the antimalarial compounds quinine and chloroquine will
most likely dock at the 5-HT binding site on the 5-HT3 receptor.
This may be due to the molecular similarity with these compounds
and 5-HT. It is plausible that these antimalarial compounds may
also bind to the 5-HT docking site at other 5-HT receptors thus
potentially act as antagonists at other 5-HT receptors. This may in
part explain the complete block of 5-HT induced contractions
following pre-application of quinine.
Other possible factors inﬂuencing the results may be down-
stream receptor interaction and/or channel blockade by the anti-
malarial drugs. It is known that 5-HT3 receptors can be expressed
presynapticly on parasympathetic and sympathetic afferents to
the gut causing release of ACh (Fox and Morton, 1990), which in
turn elicits contractions of longitudinal muscle via activation of
muscarinic ACh receptors. As quinine is known to act as a blocker
of voltage-activated currents and muscarinic activated potassium
channels (Dresviannikov et al., 2006), it is plausible that the effects
observed may have been inﬂuenced in part by a blockade of these
channels by quinine. Meﬂoquine is also known to block Kþ
channels. However it would be anticipated that a blockade of Kþ
channels would result in excitation, rather than an inhibition of
contractile responses. It was noted during the experiments that
following the initial application of quinine at 100–300 nM, there
was a clear contraction with no responses at higher doses (data
not shown). These observations would be consistent with potas-
sium channel blockade leading towards excitation and contractile
responses rather than a straightforward inhibition of the contrac-
tions. It is not clear that the results can be explained as simply a
downstream blockade of muscarinic receptor activated cation
channels. Both quinine and meﬂoquine completely antagonised
5-HT induced contractions, which may indicate an antagonism at
5-HT2 receptors, as well as 5-HT3 and 5-HT4 receptors. It is known
that 5-HT2 induced contractions are not inﬂuenced or dependent
upon cholinergic receptor activation or inhibition. Therefore this
would imply that the effects of quinine and meﬂoquine observed
upon 5-HT induced contractions cannot be due exclusively to an
interaction at muscarinic receptor activated channels.
It should be noted that this study has focused exclusively on
isolated intestinal tissue preparations. The antimalarial drugs may
have direct central effects. Ondansetron, a selective 5-HT3 antago-
nist and antiemetic drug, produces its antiemetic effect by block-
ing peripheral 5-HT3 receptors on vagal afferents and brain 5-HT3
receptors expressed in the medullary chemoreceptor zone (Gan,
2005). It is plausible that the antimalarial drugs would act at the
same central 5-HT3 receptors producing an antiemetic effect.
Meﬂoquine has the ability to cross the blood brain barrier
(Baudry et al., 1997). However, quinine and chloroquine cannot
easily cross the blood brain barrier (Hagihara et al., 2000; Silamut
et al., 1985) and this would be expected to impede any possible
antiemetic effects by these drugs by acting at central 5-HT3
receptors.
In conclusion, the present ﬁndings present an inhibition of
both 5-HT and 5-HT3 receptor-mediated contractions in both
guinea-pig and mouse ileum tissue by the antimalarial drugs
quinine, chloroquine and meﬂoquine. These results strongly
suggest that these antimalarial drugs will directly interact and
inﬂuence physiological function in the gut and may inhibit or
disrupt normal contraction reﬂex responses at high concentra-
tions. It is possible that the GI side-effects reported for these
compounds may partially be the result of antagonist action at 5-
HT3 receptors.
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Table 1
5-HT and 2-me-5-HT-evoked contraction in isolated mouse and guinea pig ileum.
Agonist EC50 (mM) pEC50 (7S.E.M.) n
Mouse ileum tissue
5-HT 27.12 7.57 (70.33) 12
2-me-5-HT 3.5 5.45 (70.58) 5
Guinea pig ileum tissue
5-HT 3.8 5.42 (70.15) 8
2-me-5-HT 9.7 5.01 (70.55) 11
Table 2
Inhibition of agonist evoked contractions in isolated mouse ileum by antimalarial
compounds.
Antimalarial IC50 (mM) pIC50 (7S.E.M.) n
Inhibition of 5-HT-evoked contractions
Quinine 12.5 4.9 (70.17) 7
Chloroquine 17.6 4.76 (70.14) 5
Meﬂoquine 0.62 6.21(70.2) 4
Inhibition of 2-me-5-HT-evoked contractions
Quinine 0.44 6.35 (70.11) 8
Chloroquine 22.9 4.64 (70.2) 7
Meﬂoquine 7.85 5.11 (70.22) 6
Table 3
Inhibition of agonist evoked contractions in isolated guinea pig ileum by anti-
malarial compounds.
Antimalarial IC50 (mM) pIC50 (7S.E.M.) n
Inhibition of 5-HT-evoked contractions
Quinine 9.46 5.02 (70.15) 6
Chloroquine 28.71 4.54 (70.1) 7
Meﬂoquine 4.78) 5.32 (70.13 5
Inhibition of 2-me-5-HT-evoked contractions
Quinine 24 4.62 (70.25) 5
Chloroquine 27.48 4.56 (70.14) 6
Meﬂoquine 2.15 5.67 (70.12) 4
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